SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Chesov D.) "

Sökning: WFRF:(Chesov D.)

  • Resultat 1-17 av 17
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Chesov, D., et al. (författare)
  • Impact of lung function on treatment outcome in patients with TB
  • 2021
  • Ingår i: The International Journal of Tuberculosis and Lung Disease. - : International Union Against Tuberculosis and Lung Disease. - 1027-3719 .- 1815-7920. ; 25:4, s. 277-284
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: The potential association between the lung function status at baseline and TB treatment outcome has not been evaluated previously. We aimed to investigate the impact of lung function status at the time of TB diagnosis on treatment outcome in patients with pulmonary TB (PTB).METHODS: A retrospective cohort study on data from all consecutive patients with culture-confirmed PTB and available spirometry test results admitted during the year 2016 to the Regional anti-TB dispensary no.1 in Kharkiv, Ukraine.RESULTS: A total of 278 patients with PTB were included into the study. The rate of negative treatment outcome (failure or death) was higher in patients with restrictive and mixed lung dysfunction than in those with normal spirometry results (25.6% vs. 6.8%, P = 0.0007; 37.5% vs. 6.8%, P = 0.003, respectively). In a logistic regression model, restrictive lung disease and mixed-type lung disease were associated with negative treatment outcome (OR 4.19, 95% CI 1.60-13.28, P = 0.007 and OR 5.46, 95% CI 1.28-24.44, P = 0.02, respectively).CONCLUSIONS: Lung function at the time of diagnosis has an important impact on treatment outcomes in patients with PTB; the more severe the restriction in lung function the higher the likelihood of a negative treatment outcome.
  •  
2.
  • Dudnyk, A, et al. (författare)
  • MDR-TB in Eastern Europe in the era of the TB elimination action framework
  • 2017
  • Ingår i: The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. - : International Union Against Tuberculosis and Lung Disease. - 1815-7920. ; 21:1, s. 2-3
  • Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
  •  
3.
  •  
4.
  •  
5.
  • Chesov, D, et al. (författare)
  • Failing treatment of multidrug-resistant tuberculosis: a matter of definition
  • 2019
  • Ingår i: The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. - : International Union Against Tuberculosis and Lung Disease. - 1815-7920. ; 23:4, s. 522-524
  • Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
  •  
6.
  •  
7.
  • Chesov, D, et al. (författare)
  • Molecular-based tuberculosis drug susceptibility testing: one size fits all?
  • 2019
  • Ingår i: The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. - : International Union Against Tuberculosis and Lung Disease. - 1815-7920. ; 23:8, s. 879-880
  • Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
  •  
8.
  • Crudu, V, et al. (författare)
  • Nosocomial transmission of multidrug-resistant tuberculosis
  • 2015
  • Ingår i: The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. - : International Union Against Tuberculosis and Lung Disease. - 1815-7920. ; 19:12, s. 1520-1523
  • Tidskriftsartikel (refereegranskat)
  •  
9.
  •  
10.
  • Dudnyk, A, et al. (författare)
  • Mission impossible: the End TB strategy
  • 2018
  • Ingår i: The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. - : International Union Against Tuberculosis and Lung Disease. - 1815-7920. ; 22:2, s. 121-122
  • Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
  •  
11.
  •  
12.
  • Lange, C, et al. (författare)
  • Clofazimine for the treatment of multidrug-resistant tuberculosis
  • 2019
  • Ingår i: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. - : Elsevier BV. - 1469-0691. ; 25:2, s. 128-130
  • Tidskriftsartikel (refereegranskat)
  •  
13.
  •  
14.
  •  
15.
  • Lange, C., et al. (författare)
  • Management of patients with multidrug-resistant tuberculosis
  • 2019
  • Ingår i: The International Journal of Tuberculosis and Lung Disease. - : INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D). - 1027-3719 .- 1815-7920. ; 23:6, s. 645-662
  • Tidskriftsartikel (refereegranskat)abstract
    • The emergence of multidrug-resistant tuberculosis (MDR-TB; defined as resistance to at least rifampicin and isoniazid) represents a growing threat to public health and economic growth. Never before in the history of mankind have more patients been affected by MDR-TB than is the case today. The World Health Organization reports that MDR-TB outcomes are poor despite staggeringly high management costs. Moreover, treatment is prolonged, adverse events are common, and the majority of affected patients do not receive adequate treatment. As MDR-TB strains are often resistant to one or more second-line anti-TB drugs, in-depth genotypic and phenotypic drug susceptibility testing is needed to construct personalised treatment regimens to improve treatment outcomes. For the first time in decades, the availability of novel drugs such as bedaquiline allow us to design potent and well-tolerated personalised MDR-TB treatment regimens based solely on oral drugs. In this article, we present management guidance to optimise the diagnosis, algorithm-based treatment, drug dosing and therapeutic drug monitoring, and the management of adverse events and comorbidities, associated with MDR-TB. We also discuss the role of surgery, physiotherapy, rehabilitation, palliative care and smoking cessation in patients with MDR-TB. We hope that incorporating these recommendations into patient care will be helpful in optimising treatment outcomes, and lead to more MDR-TB patients achieving a relapse-free cure.
  •  
16.
  •  
17.
  • Merker, M, et al. (författare)
  • In reply
  • 2016
  • Ingår i: The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. - : International Union Against Tuberculosis and Lung Disease. - 1815-7920. ; 20:3, s. 424-424
  • Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-17 av 17

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy